These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 25862209

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.
    Long YO, Higuchi RI, Caferro TR, Lau TL, Wu M, Cummings ML, Martinborough EA, Marschke KB, Chang WY, López FJ, Karanewsky DS, Zhi L.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2967-71. PubMed ID: 18400499
    [Abstract] [Full Text] [Related]

  • 23. Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage.
    Dubois V, Simitsidellis I, Laurent MR, Jardi F, Saunders PT, Vanderschueren D, Claessens F.
    Endocrinology; 2015 Dec 01; 156(12):4522-33. PubMed ID: 26393303
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
    Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG.
    Endocrinology; 2007 Jan 01; 148(1):4-12. PubMed ID: 17008401
    [Abstract] [Full Text] [Related]

  • 26. 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties.
    Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schänzer W, Thevis M, Vollmer G, Zierau O, Diel P.
    Toxicol Lett; 2006 Aug 20; 165(2):149-55. PubMed ID: 16621347
    [Abstract] [Full Text] [Related]

  • 27. Enhanced evaluation of selective androgen receptor modulators in vivo.
    Otto-Duessel M, He M, Adamson TW, Jones JO.
    Andrology; 2013 Jan 20; 1(1):29-36. PubMed ID: 23258627
    [Abstract] [Full Text] [Related]

  • 28. Cell-specific activation of the human skeletal alpha-actin by androgens.
    Hong MH, Sun H, Jin CH, Chapman M, Hu J, Chang W, Burnett K, Rosen J, Negro-Vilar A, Miner JN.
    Endocrinology; 2008 Mar 20; 149(3):1103-12. PubMed ID: 18063690
    [Abstract] [Full Text] [Related]

  • 29. Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold.
    Ng RA, Lanter JC, Alford VC, Allan GF, Sbriscia T, Lundeen SG, Sui Z.
    Bioorg Med Chem Lett; 2007 Mar 15; 17(6):1784-7. PubMed ID: 17197181
    [Abstract] [Full Text] [Related]

  • 30. A selective androgen receptor modulator for hormonal male contraception.
    Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT.
    J Pharmacol Exp Ther; 2005 Feb 15; 312(2):546-53. PubMed ID: 15347734
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.
    Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT.
    Mol Endocrinol; 2008 Nov 15; 22(11):2448-65. PubMed ID: 18801930
    [Abstract] [Full Text] [Related]

  • 33. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.
    Yarrow JF, McCoy SC, Borst SE.
    Steroids; 2010 Jun 15; 75(6):377-89. PubMed ID: 20138077
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor.
    Nellemann C, Dalgaard M, Holst B, Bonefeld-Jørgensen EC, Vinggaard AM.
    Mol Cell Endocrinol; 2005 Jun 15; 237(1-2):25-35. PubMed ID: 15925091
    [Abstract] [Full Text] [Related]

  • 36. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
    Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.
    J Med Chem; 2009 Jun 25; 52(12):3597-617. PubMed ID: 19432422
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction.
    Monks DA, O'Bryant EL, Jordan CL.
    J Comp Neurol; 2004 May 17; 473(1):59-72. PubMed ID: 15067718
    [Abstract] [Full Text] [Related]

  • 39. Selective androgen receptor modulators: in pursuit of tissue-selective androgens.
    Omwancha J, Brown TR.
    Curr Opin Investig Drugs; 2006 Oct 17; 7(10):873-81. PubMed ID: 17086931
    [Abstract] [Full Text] [Related]

  • 40. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
    Nejishima H, Yamamoto N, Suzuki M, Furuya K, Nagata N, Yamada S.
    Prostate; 2012 Oct 01; 72(14):1580-7. PubMed ID: 22430536
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.